Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

  • End date
    Aug 23, 2023
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 23 March 2022
platelet count
renal function
measurable disease
neutrophil count
liver metastasis
programmed cell death 1 ligand 1
ovarian suppression
vascular endothelial growth factor
line of therapy
renal function tests
metastatic renal cell carcinoma


The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.

Condition Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Treatment Avelumab, Talazoparib
Clinical Study IdentifierNCT04068831
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on23 March 2022


Yes No Not Sure

Inclusion Criteria

Biopsy proven, histological confirmed renal cell carcinoma (RCC) or renal medullary carcinoma (RMC).. Patients with surgery and biopsy at outside institutions will be eligible for this protocol once archival material is reviewed and the above diagnosis confirmed by genitourinary pathology review at Memorial Sloan Kettering Cancer Center (MSKCC)
Cohort 1: (Closed to Accrual)
Presence of VHLalteration by next-generation sequencing (NGS) with a stateapproved assay
Patients must have radiographic evidence of disease progression after treatment with at least one prior PD-1 or PD-L1 agent, and one prior VEGF inhibitor
Maximum 3 prior lines of therapy
Cohort 2
For FH/SDH patients FH- or SDH- expression-loss by immunohistochemistry (IHC) or alteration (somatic or germline) in FH or SDH per NGS with a state-approved assay
For Renal Medullary Carcinoma (RMC) patients: histologic confirmation of RMC (no IHC/NGS criteria required)
At least one prior line of therapy
For FH/SDH patients Patients must have radiographic evidence of disease progression after treatment with at least one prior line of therapy (one prior PD-1/PD-L1 and/or VEGF inhibitor)
For Renal Medullary Carcinoma (RMC) patients prior radiographic evidence of disease progression on/after at least one line of chemotherapy (e.g. carboplatin / paclitaxel, carboplatin / paclitaxel / bevacizumab, carboplatin / gemcitabine, and gemcitabine / doxorubicin)
No maximum lines of therapy
Both Cohorts 1 & 2
Adequate Hematologic Function
Absolute Neutrophil Count ≥ 1.5 x 10^9 / L
Platelet Count ≥ 100 x 10^9 / L
Hemoglobin ≥ 9 g/dL
No transfusion of packed red blood cells or platelets within 21 days of Cycle 1 Day 1
Adequate Renal Function ≥ 30 ml/min according to the Cockcroft-Gault Equation
Patients with moderate renal impairment (creatinine clearance 30-59 by Cockcroft-Gault EquationI) will start with a reduced dose of talazoparib
Adequate Hepatic Function including
Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
AST ≤ 3 x upper limit of normal (ULN) without liver metastasis
ALT ≤ 3 x upper limit of normal (ULN) without liver metastasis
AST or ALT ≤ 5 x upper limit of normal (ULN) for patients with liver metastasis
Patients with known Gilbert's syndrome may be included if total bilirubin ≤ x 3 ULN
Eastern Cooperative Group (ECOG) Performance Status 0-2
Patients must have measurable disease by RECIST v1.1. At least one measurable lesion should not have been previously irradiated
Women of childbearing potential must have negative serum pregnancy testing at screening. All women will be considered childbearing potential unless meeting criteria
Achieved post-menopausal status as defined by cessation of regular menses for at least
Documented hysterectomy or bilateral oophorectomy surgery
consecutive months with no alternative pathological or physiological cause
and have follicular stimulation hormone showing postmenopausal state. Women
Medically confirmed ovarian failure
who have been amenorrhoeic for ≥12 months are still considered to be of
Sexually active participants and their partners must agree to use medically accepted methods of contraception (i.e. barrier methods including condoms, female condom, or diaphragm with spermicidal gel) during the study and for 7 months after the last dose of the study treatment for females, and 4 months for males
childbearing potential if the amenorrhea is possibly due to prior
chemotherapy, anorexia, low body weight, ovarian suppression, anti-estrogen
Patients must be willing and able to comply with trial protocol. This includes adhering to the treatment plan, scheduled visits, laboratory and other study procedures
therapy or other medically inducible reasons
Recovery of baseline CTCAE v5.0 grade ≤1 toxicities related to prior study treatments unless adverse events are clinically non-significant and/or stable on supportive therapy if needed

Exclusion Criteria

Patients < 18 years old
Patients who are pregnant or breast-feeding. Fertile patients who are unwilling or unable to use two methods of contraception (at least one of which considered highly effective) for duration of study and after 7 months after last dose of study treatment for female, and 4 months for males
Patients who had prior immune checkpoint blockade therapy (either anti-PD-1, antiPD -L1 and/or anti-CTLA-4) discontinued due to development of an immune related adverse event
Prior diagnosis of myelodysplastic syndrome (MDS) or diagnosis of other malignancy that requires anti-cancer directed therapy within the last 24 months. Exclusions include those cancers that are considered cured by local therapy (i.e.Basal cell carcinoma, squamous cell carcinoma, ducal carcinoma in situ of breast, bladder of cervix) or other cancers that have low malignant potential and do not require systemic therapy (i.e. Gleason-grade <6 prostate adenocarcinoma, borderline ovarian malignancy / low malignant potential)
Prior treatment with talazoparib or other agents that target PARP
Treatment with anti-cancer therapies within 21 days or five half-lives, whichever shorter, of start date, including monoclonal antibody, cytotoxic therapy, or another investigational agent. There is no specific time window between last PD-1/PD-L1 therapy and start date of new therapy on protocol
Significant vascular disease (i.e. aortic aneurysm requiring surgical repair, recent arterial thrombosis) within 6 months prior to first dose of therapy
Evidence of bleeding diathesis or significant unexplained coagulopathy (i.e. absent of anticoagulation)
Clinical signs or symptoms of gastrointestinal obstruction requirement parenteral hydration, parenteral nutrition, or feeding tube
Uncontrolled effusion management (pleural effusion, pericardial effusion, or ascites) which requires recurrent drainage procedures
Patients treated with systemic immunosuppressants; except for
Local steroid use is permitted (e.g. intranasal, topical, inhaled, or local steroid injection, i.e. intra-articular)
Prior organ transplantation including allogeneic stem cell transplant
No active infection requiring parenteral antibiotic therapy
Prior diagnosis of HIV/AIDS
History of either positive HCV RNA viral load or anti-HCV antibody screening detectable; HBV infection with HBV surface antigen detection and/or positive HBV DNA viral load
chronic physiologic replacement of ≤ 10mg prednisone (or equivalent) for treatment of adrenal insufficiency; Steroids required for pre-medication reactions
Live vaccination within 4 weeks of first dose of therapy. All vaccines except inactivated are prohibited while on study
Patients with autoimmune disease that may worsen during immune checkpoint blockade
Severe acute or chronic medical conditions which may significantly increase the risk of study participants, per treating investigator's discretion
therapy are excluded. Patients with diabetes type I, vitiligo, psoriasis
hypo- or hyperthyroid disease not requirement immunosuppressive treatment as
Radiation therapy to any site (including bone) <2 weeks prior to the first dose of therapy. Patients with clinically relevant ongoing complications from prior radiation therapy, per investigators' assessment, are not eligible
Symptomatic brain metastasis or leptomeningeal disease requiring steroid use. Patients are eligible if they neurologically stable for 4 weeks, and have completed radiation therapy or surgery, and recovered from side effects. Patients must have discontinued steroid therapy for at least 2 weeks prior to first dose of study treatment
above are eligible
Current or anticipated use of potent P-gp inhibitors within 7 days prior to randomization or anticipated use during the study. Please see Appendix 5 for a list of potent P-gp inhibitors
Inability to swallow capsules, known intolerance to talazoparib or its excipients, known malabsorption syndrome, or other conditions which impair intestinal absorption
Investigator site staff members directly involved in study conduct, including but not limited to their family members, or patients who are Pfizer members, including their family members, who are directly involved in study conduct
Known hypersensitivity to talazoparib or avelumab, or any component in formulations. Patients with known hypersensitivity to monoclonal antibodies (Grade ≥3 by CTCAE v5.0)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note